Your browser is no longer supported. Please, upgrade your browser.
Settings
VVUS VIVUS, Inc. daily Stock Chart
VVUS [NASD]
VIVUS, Inc.
Index- P/E5.29 EPS (ttm)0.21 Insider Own0.90% Shs Outstand105.60M Perf Week-5.17%
Market Cap116.16M Forward P/E- EPS next Y-0.45 Insider Trans-76.74% Shs Float99.30M Perf Month-5.98%
Income23.30M PEG6.61 EPS next Q-0.14 Inst Own36.80% Short Float6.25% Perf Quarter-13.39%
Sales124.30M P/S0.93 EPS this Y124.80% Inst Trans4.92% Short Ratio11.07 Perf Half Y1.85%
Book/sh0.17 P/B6.47 EPS next Y13.50% ROA8.20% Target Price2.80 Perf Year-1.79%
Cash/sh2.55 P/C0.43 EPS next 5Y0.80% ROE-136.10% 52W Range0.93 - 1.85 Perf YTD-4.35%
Dividend- P/FCF- EPS past 5Y19.10% ROI21.40% 52W High-40.54% Beta0.72
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin91.50% 52W Low18.28% ATR0.05
Employees65 Current Ratio6.30 Sales Q/Q434.60% Oper. Margin44.80% RSI (14)48.20 Volatility3.71% 4.17%
OptionableYes Debt/Eq13.26 EPS Q/Q549.80% Profit Margin18.80% Rel Volume0.32 Prev Close1.09
ShortableYes LT Debt/Eq12.78 EarningsMar 08 AMC Payout0.00% Avg Volume560.41K Price1.10
Recom2.50 SMA20-0.90% SMA50-2.05% SMA200-3.80% Volume181,208 Change0.92%
May-04-16Downgrade WallachBeth Buy → Hold
Nov-05-15Upgrade WallachBeth Hold → Buy $2.30 → $2.80
Jul-31-15Reiterated RBC Capital Mkts Outperform $6 → $4
Jan-23-15Initiated RBC Capital Mkts Outperform $6
Feb-25-14Reiterated WallachBeth Hold $11 → $8
Nov-15-13Initiated WallachBeth Hold $11
Oct-03-13Upgrade Cowen Hold → Outperform $19
Jul-19-13Downgrade Needham Buy → Hold
Jan-18-13Reiterated MLV & Co Buy $40 → $21
Sep-24-12Reiterated Needham Buy $38 → $32
Jul-19-12Reiterated MLV & Co Buy $34 → $40
Jul-18-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
Jul-18-12Downgrade Brean Murray Buy → Hold
Apr-30-12Reiterated MLV & Co Buy $30 → $34
Feb-23-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
Feb-23-12Upgrade Brean Murray Sell → Hold $2
Feb-23-12Reiterated MLV & Co Buy $22 → $30
Feb-23-12Reiterated JMP Securities Mkt Outperform $16 → $45
Jan-17-12Reiterated MLV & Co Buy $16 → $22
Jan-05-12Initiated Rodman & Renshaw Mkt Perform
Mar-15-17 11:16AM  7 Most Popular Diet Pills That Work Fast Without Exercise at Insider Monkey
10:29AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
Mar-14-17 01:04PM  VIVUS INC Financials
12:04PM  Top 10 Long/Short Estimize Signal Scores [Week 3/13]
Mar-13-17 04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Mar-10-17 09:30AM  Markets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS Accesswire -6.61%
Mar-09-17 10:59AM  VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y +16.35%
Mar-08-17 11:37PM  Edited Transcript of VVUS earnings conference call or presentation 8-Mar-17 9:30pm GMT
05:38PM  Vivus posts 4Q profit
04:17PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:10PM  VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results Marketwired
04:05PM  VIVUS INC Files SEC form 10-K, Annual Report
07:07AM  Q4 2016 VIVUS Inc Earnings Release - After Market Close
Feb-28-17 08:00AM  VIVUS Announces Date of 2016 Fourth Quarter Business Update and Financial Results Teleconference Marketwired
Feb-23-17 09:39AM  [2/23] This Weeks Earnings Revisions Movers +5.41%
Feb-22-17 09:45AM  Biotech's Rally Shows No Signs of Slowing Down: Today's Reports on Eyegate Pharmaceuticals and VIVUS Accesswire
Jan-31-17 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-18-17 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-17-17 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-11-17 03:24PM  VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan-10-17 08:33AM  VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-09-17 04:07PM  VIVUS INC Files SEC form 8-K, Other Events
09:00AM  VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH) Marketwired
Jan-03-17 04:20PM  VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?
Dec-29-16 05:29PM  4 Biotech Stocks with Bright Prospects in 2017
Dec-27-16 02:05PM  ETFs with exposure to VIVUS, Inc. : December 27, 2016 -5.56%
Dec-14-16 12:37AM  Do Hedge Funds Love VIVUS, Inc. (VVUS)? at Insider Monkey
Dec-13-16 01:42PM  ETFs with exposure to VIVUS, Inc. : December 13, 2016
Dec-05-16 11:10AM  Increased Earnings Estimates Seen for VIVUS (VVUS): Can It Move Higher?
Dec-01-16 04:20PM  5 Top Performing Biotechnology Stocks of November +5.22%
Nov-21-16 08:25AM  VIVUS (VVUS) Shows Strength: Stock Adds 5.1% in Session
Nov-18-16 01:43PM  ETFs with exposure to VIVUS, Inc. : November 18, 2016 +5.13%
Nov-14-16 04:12PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Submission of Matters to a Vote of Secur
11:25AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
Nov-11-16 02:51PM  VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3
Nov-09-16 09:25PM  Edited Transcript of VVUS earnings conference call or presentation 9-Nov-16 9:30pm GMT
06:25PM  Vivus reports 3Q loss
04:44PM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Security
04:10PM  VIVUS Reports 2016 Third Quarter Financial Results Marketwired
07:07AM  Q3 2016 VIVUS Inc Earnings Release - After Market Close
Oct-26-16 05:00PM  VIVUS Announces Date of 2016 Third Quarter Business Update and Financial Results Teleconference Marketwired
Oct-12-16 09:20AM  Mylan Up on EpiPen Medicaid Settlement, Cuts 2016 Outlook
Oct-06-16 08:55AM  Earnings Estimates Moving Higher for VIVUS (VVUS): Time to Buy?
Oct-05-16 09:30AM  The Zacks Analyst Blog Highlights: VIVUS, Geron, Achillion Pharmaceuticals, Anika Therapeutics and ANI Pharmaceuticals
Oct-04-16 05:34PM  VIVUS Licenses Stendra Rights to Metuchen Pharmaceuticals
01:53PM  Biotech Mergers Run the Show: 5 Small-Cap Stocks for Q4
10:05AM  Roche Alecensa Wins Second Breakthrough Status in the U.S.
Oct-03-16 08:36AM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Stateme
Sep-28-16 04:51PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
05:53AM  Myriad Genetics to Present myRisk Data at Seattle Conference
Sep-27-16 10:24AM  ETFs with exposure to VIVUS, Inc. : September 27, 2016
Sep-09-16 11:33AM  ETFs with exposure to VIVUS, Inc. : September 9, 2016
Sep-06-16 04:09PM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreem
Aug-29-16 04:37PM  VIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
04:30PM  VIVUS Extends Return Date of STENDRA Commercial Rights Marketwired
Aug-26-16 10:50AM  ETFs with exposure to VIVUS, Inc. : August 26, 2016
Aug-12-16 02:49PM  ETFs with exposure to VIVUS, Inc. : August 12, 2016
Aug-11-16 10:35AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
Aug-09-16 04:08PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Aug-07-16 02:41PM  Edited Transcript of VVUS earnings conference call or presentation 4-Aug-16 8:30pm GMT
Aug-04-16 05:01PM  Vivus reports 2Q loss
04:23PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:15PM  VIVUS Reports 2016 Second Quarter Financial Results Marketwired
04:04PM  VIVUS INC Files SEC form 10-Q, Quarterly Report
07:07AM  Q2 2016 VIVUS Inc Earnings Release - After Market Close
Jul-27-16 04:22PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:15PM  VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents Marketwired
Jul-26-16 04:15PM  VIVUS Announces Date of 2016 Second Quarter Business Update and Financial Results Teleconference Marketwired
Jul-22-16 06:03AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jul-21-16 06:01PM  VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation Marketwired
Jun-30-16 04:22PM  VIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
04:15PM  VIVUS to Extend Return Date of STENDRA Commercial Rights Marketwired
12:45PM  ETFs with exposure to VIVUS, Inc. : June 30, 2016
Jun-21-16 04:07PM  VIVUS INC Files SEC form 8-K, Other Events
Jun-17-16 05:37PM  ETFs with exposure to VIVUS, Inc. : June 17, 2016
Jun-09-16 08:58AM  Orexigen Stock Gains More than 50% on Markman Hearing
Jun-03-16 03:48PM  ETFs with exposure to VIVUS, Inc. : June 3, 2016
May-23-16 09:01AM  Im traveling this week, so Im not able to write a new blog post, but I thought I would share the video of the presentation J. Carlo Cannell and I made at last years Stansberry Conference in Las Vegas. Im scheduled to present at the conf
May-18-16 11:01PM  ETFs with exposure to VIVUS, Inc. : May 19, 2016
May-17-16 04:31PM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q1, 2016 By the Numbers
11:31AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of VIVUS Inc. - VVUS PR Newswire
May-16-16 12:53PM  Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
May-06-16 04:12PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
May-05-16 04:14PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
May-04-16 10:28AM  Vivus downgraded by WallachBeth -8.67%
08:09AM  VIVUS (VVUS) Q1 Loss Narrower but Qsymia Sales Decline
08:07AM  Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
May-03-16 09:34PM  Edited Transcript of VVUS earnings conference call or presentation 3-May-16 8:30pm GMT -5.06%
04:37PM  Vivus reports 1Q loss AP
04:15PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  Vivus Reports 2016 First Quarter Financial Results Marketwired
04:05PM  VIVUS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q1 2016 VIVUS Inc Earnings Release - After Market Close CCBN
Apr-19-16 06:00PM  VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference Marketwired
Apr-11-16 11:40AM  VIVUS (VVUS) Upgraded to Hold on Strong Fundamentals
Apr-07-16 09:30AM  Biotech Volatility Both Good And Bad Accesswire
Apr-04-16 03:45PM  ETFs with exposure to VIVUS, Inc. : April 4, 2016 +6.71%
08:05AM  VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Mar-25-16 10:06AM  ETFs with exposure to VIVUS, Inc. : March 25, 2016
Mar-14-16 04:12PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits +6.78%
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NORTH TIDE CAPITAL, LLC10% OwnerMar 10Sale1.1777,00090,24410,466,700Mar 10 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 09Sale1.21722,400873,24910,543,700Mar 10 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 08Sale1.05350,000368,34011,266,100Mar 10 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 07Sale1.08145,100156,15111,616,100Mar 07 05:18 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 06Sale1.1014,80016,23011,761,200Mar 07 05:18 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 03Sale1.1132,90036,36311,776,000Mar 07 05:18 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 02Sale1.1320,00022,50011,808,900Mar 02 05:16 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 01Sale1.13114,600130,04611,828,900Mar 02 05:16 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 28Sale1.1225,50028,59311,943,500Mar 02 05:16 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 27Sale1.13150,000168,96511,969,000Feb 27 05:42 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 24Sale1.1433,00037,50512,119,000Feb 27 05:42 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 23Sale1.16150,000174,01512,152,000Feb 27 05:42 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 22Sale1.11109,336121,58212,302,000Feb 22 04:52 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 21Sale1.1052,16457,61012,411,336Feb 22 04:52 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 17Sale1.1130033412,463,500Feb 22 04:52 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 16Sale1.10150,000165,25012,463,800Feb 16 05:35 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 15Sale1.1140,09044,50012,613,800Feb 16 05:35 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 14Sale1.10115,000126,50012,653,890Feb 16 05:35 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 13Sale1.1067,00074,02212,768,890Feb 13 05:13 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 10Sale1.1146,00850,83912,835,890Feb 13 05:13 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 09Sale1.1163,40270,42112,881,898Feb 13 05:13 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 08Sale1.06529,300561,74212,945,300Feb 08 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 07Sale1.116,2006,86113,474,600Feb 08 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 06Sale1.1028,02730,94213,480,800Feb 08 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 03Sale1.1253,43359,69013,508,827Feb 03 04:40 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 02Sale1.133,2003,61613,562,260Feb 03 04:40 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 01Sale1.1322,00024,94113,565,460Feb 03 04:40 PM
Varghese Santosh TChief Medical OfficerJan 28Sale1.1142947674,037Jan 31 06:43 PM
Varghese Santosh TChief Medical OfficerDec 31Sale1.1213,79015,47874,466Jan 04 06:48 PM
Varghese Santosh TChief Medical OfficerOct 01Sale1.1471080988,256Oct 04 07:35 PM
Varghese Santosh TChief Medical OfficerAug 02Sale1.0712,55913,43888,966Aug 02 07:07 PM
Varghese Santosh TVP, Medical & Reg AffairsJul 01Sale1.21366443101,525Jul 06 05:12 PM
Varghese Santosh TChief Medical OfficerApr 07Sale1.65329543101,891Apr 11 09:33 PM
NORTH TIDE CAPITAL, LLC10% OwnerApr 01Buy1.402,1603,02813,587,460Apr 05 04:08 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 31Buy1.36172,300234,22513,585,300Mar 31 05:15 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 30Buy1.25100,000125,45013,413,000Mar 31 05:15 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 29Buy1.21111,000133,84313,313,000Mar 31 05:15 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 28Buy1.13177,000199,39013,202,000Mar 28 04:46 PM